[go: up one dir, main page]

NO20082768L - Levodopa prodroge mesylat, sammensetninger og anvendelser derav - Google Patents

Levodopa prodroge mesylat, sammensetninger og anvendelser derav

Info

Publication number
NO20082768L
NO20082768L NO20082768A NO20082768A NO20082768L NO 20082768 L NO20082768 L NO 20082768L NO 20082768 A NO20082768 A NO 20082768A NO 20082768 A NO20082768 A NO 20082768A NO 20082768 L NO20082768 L NO 20082768L
Authority
NO
Norway
Prior art keywords
compositions
levodopa prodrug
prodrug mesylate
mesylate
methods
Prior art date
Application number
NO20082768A
Other languages
English (en)
Inventor
Jia-Ning Xiang
Cindy X Zhou
Mark Nguyen
Xuedong Dai
Jianhua Li
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of NO20082768L publication Critical patent/NO20082768L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)

Abstract

(2R)-2-Fenylkarbonyloksypropyl(2S)-2-amino-3-(3,4-dihydroksyfenyl)propanoat mesylat og krystallform av det, metoder for fremstilling av dette, farmasøytiske sammensetninger av dette og metoder for å bruke dette ved behandling av sykdommer eller lidelser som for eksempel Parkinsons sykdom.
NO20082768A 2005-12-05 2008-06-16 Levodopa prodroge mesylat, sammensetninger og anvendelser derav NO20082768L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74187605P 2005-12-05 2005-12-05
PCT/US2006/046273 WO2007067495A2 (en) 2005-12-05 2006-12-04 Levodopa prodrug mesylate, compositions thereof, and uses thereof

Publications (1)

Publication Number Publication Date
NO20082768L true NO20082768L (no) 2008-06-24

Family

ID=38123406

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082768A NO20082768L (no) 2005-12-05 2008-06-16 Levodopa prodroge mesylat, sammensetninger og anvendelser derav

Country Status (20)

Country Link
US (5) US7563821B2 (no)
EP (1) EP1959948B1 (no)
JP (1) JP5153641B2 (no)
KR (1) KR101396639B1 (no)
CN (1) CN101365439B (no)
AU (1) AU2006322051B2 (no)
BR (1) BRPI0619425A2 (no)
CA (1) CA2631643C (no)
CY (1) CY1113108T1 (no)
DK (1) DK1959948T3 (no)
ES (1) ES2391575T3 (no)
IL (1) IL191937A (no)
NO (1) NO20082768L (no)
NZ (1) NZ569485A (no)
PL (1) PL1959948T3 (no)
PT (1) PT1959948E (no)
RU (1) RU2429223C2 (no)
TW (1) TWI403493B (no)
WO (1) WO2007067495A2 (no)
ZA (1) ZA200805511B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
RU2365580C2 (ru) * 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
PT1959948E (pt) 2005-12-05 2012-09-12 Xenoport Inc Mesilato de pró-fármaco de levodopa, suas composições e suas utilizações
WO2008034087A2 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
TW200843732A (en) * 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US8802681B2 (en) 2008-10-17 2014-08-12 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
RU2513090C2 (ru) 2009-04-17 2014-04-20 Мерц Фарма Гмбх Унд Ко. Кгаа Синтез мезилата 1-амино-1,3,3,5,5-пентаметилциклогексана
JP2013503862A (ja) 2009-09-08 2013-02-04 シグネーチャー セラピューティクス，インク． 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
AU2010315892B2 (en) * 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
JP5423905B2 (ja) * 2010-12-02 2014-02-19 小野薬品工業株式会社 新規化合物及びその医薬用途
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
ES2584634T3 (es) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
EP2683394B1 (en) 2011-03-09 2021-01-06 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
JP2014530913A (ja) * 2011-10-24 2014-11-20 エンドゥ ファーマシューティカルズ ソリューションズ インコーポレイティド 移植可能ラサギリン組成物及びその治療方法
US9575244B2 (en) 2013-01-04 2017-02-21 Bal Makund Dhar Light guide apparatus and fabrication method thereof
FR3008411B1 (fr) 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
CN103554078B (zh) * 2013-11-22 2016-03-02 浙江安赛生物科技有限公司 低级醛（c2-c10）丙二醇缩醛的合成方法
SG11201703170RA (en) * 2014-10-21 2017-05-30 Abbvie Inc Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
KR102324042B1 (ko) 2016-07-14 2021-11-09 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 그의 용도
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
CN112770734B (zh) 2018-09-13 2024-08-20 堪培拉大学 抑制方法
CA3107139C (en) * 2018-09-21 2023-01-03 Kashiv Biosciences, Llc Extended release compositions comprising trihexyphenidyl
CN113015531A (zh) 2018-11-15 2021-06-22 艾伯维公司 用于皮下施用的药物调配物
US20220267295A1 (en) * 2019-07-17 2022-08-25 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
PE20231850A1 (es) 2020-09-09 2023-11-21 Crinetics Pharmaceuticals Inc Formulaciones de un modulador de somatostatina
WO2022056360A1 (en) * 2020-09-11 2022-03-17 Synagile Corporation Methods for continuous oral drug delivery
CA3230025A1 (en) 2021-09-29 2023-04-06 Lynn Kirkpatrick Enzyme-cleavable methadone prodrugs and methods of use thereof
CN116500162A (zh) * 2023-04-27 2023-07-28 北京和合医学诊断技术股份有限公司 一种同时检测6种药物浓度的液相色谱-质谱分析方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3983138A (en) 1973-09-25 1976-09-28 Merck & Co., Inc. Amino acid esters
US4038411A (en) 1973-09-25 1977-07-26 Merck & Co., Inc. Antihypertensive amino acid esters
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
FR2365341A1 (fr) * 1976-09-28 1978-04-21 Synthelabo Derives de l'acide l-(phenyl-3 amino-2 propionyloxy)-2 acetique
US4180509A (en) * 1977-07-01 1979-12-25 Merrell Toraude Et Compagnie α-Ethynyl tryptophanes
US4311706A (en) 1980-01-22 1982-01-19 Interx Research Corporation Novel dopa/dopamine prodrugs
JPS5824547A (ja) 1981-08-06 1983-02-14 Nippon Zoki Pharmaceut Co Ltd 新規アミノ酸誘導体
US4914222A (en) 1983-08-29 1990-04-03 Merck & Co., Inc. Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process
LU85757A1 (fr) 1985-02-04 1986-09-02 Univ Catholique Louvain Derives nouveaux de la l-dopa,procedes pour leur preparation et compositions pharmaceutiques concernant de tels composes
US4873263A (en) 1985-12-30 1989-10-10 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
JPS62258347A (ja) * 1986-05-02 1987-11-10 Banyu Pharmaceut Co Ltd 無水結晶形態のｌ−スレオ−３−（３，４−ジヒドロキシフエニル）−ｎ−メチルセリン
DE3779500T2 (de) 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4983400A (en) 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
JPH07278076A (ja) * 1994-04-12 1995-10-24 Ajinomoto Co Inc Ｌ−フェニルアラニン・モノメチル硫酸塩の晶析方法
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
GB2348371B (en) 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
AU2001296703A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
WO2003041646A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20030158254A1 (en) 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
AU2003293423A1 (en) * 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
RU2365580C2 (ru) * 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
WO2005121070A1 (en) 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
DE102005022276A1 (de) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
PT1959948E (pt) 2005-12-05 2012-09-12 Xenoport Inc Mesilato de pró-fármaco de levodopa, suas composições e suas utilizações
US9603941B2 (en) 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
TW200843732A (en) * 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
AU2010315892B2 (en) * 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use

Also Published As

Publication number Publication date
RU2008127312A (ru) 2010-01-20
US7563821B2 (en) 2009-07-21
RU2429223C2 (ru) 2011-09-20
HK1121381A1 (en) 2009-04-24
US20120296109A1 (en) 2012-11-22
IL191937A (en) 2014-07-31
US7893105B2 (en) 2011-02-22
WO2007067495A3 (en) 2007-09-27
JP2009520690A (ja) 2009-05-28
ZA200805511B (en) 2010-02-24
ES2391575T3 (es) 2012-11-27
JP5153641B2 (ja) 2013-02-27
US20110111062A1 (en) 2011-05-12
EP1959948B1 (en) 2012-07-18
DK1959948T3 (da) 2012-08-20
CN101365439A (zh) 2009-02-11
US8193242B2 (en) 2012-06-05
TWI403493B (zh) 2013-08-01
EP1959948A2 (en) 2008-08-27
BRPI0619425A2 (pt) 2011-10-04
CY1113108T1 (el) 2016-04-13
AU2006322051B2 (en) 2011-09-29
US20090326067A1 (en) 2009-12-31
AU2006322051A1 (en) 2007-06-14
PL1959948T3 (pl) 2012-12-31
KR20080073365A (ko) 2008-08-08
IL191937A0 (en) 2009-08-03
KR101396639B1 (ko) 2014-05-21
US20090156679A1 (en) 2009-06-18
CA2631643C (en) 2015-07-07
PT1959948E (pt) 2012-09-12
WO2007067495A2 (en) 2007-06-14
CA2631643A1 (en) 2007-06-14
NZ569485A (en) 2011-06-30
US20070225366A1 (en) 2007-09-27
CN101365439B (zh) 2012-12-26
US7968597B2 (en) 2011-06-28
TW200804239A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
NO20082768L (no) Levodopa prodroge mesylat, sammensetninger og anvendelser derav
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
GT200400239A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
NZ591873A (en) Co-crystals of tramadol and nsaids
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
ATE417607T1 (de) Sphingolipide gegen krankhafte prozesse in lipid rafts
WO2011056240A3 (en) Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application